US71678J2096 - Common Stock
PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
NEW YORK, NY / NewsDirect / March 11th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of Petros Pharmaceuticals Inc a company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs.
Petros Pharmaceuticals (PTPI) shares slipped -9.3% in early trading on Friday after the company said it had secured $15M private placement financing. The micro-cap health company said...
It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday!